Immunovant Sciences GmbH

Quick facts

Phase 3 pipeline

• IMVT-1402 · Immunology
  IMVT-1402 is a neonatal Fc receptor (FcRn) antagonist that reduces circulating immunoglobulin levels by blocking FcRn-mediated recycling of IgG antibodies.
• Matching Placebo SC
  This is a placebo control formulation used in clinical trials to match the subcutaneous administration route of an active investigational drug.

Phase 2 pipeline

• RVT-1401

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Immunovant Sciences GmbH portfolio CI brief
• Immunovant Sciences GmbH pipeline updates RSS